Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Wenyuan XiongSofia Friberg HietalaJoakim NybergOrestis PapasouliotisAndreas JohneKarin BerghoffKosalaram GotetiJennifer DongPascal GirardKarthik VenkatakrishnanRainer StrotmannPublished in: Cancer chemotherapy and pharmacology (2022)
NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992.